CRISPR Therapeutics AG
NASDAQ:CRSP
CRISPR Therapeutics AG
NASDAQ:CRSP
Price:
51.48 USD
-3.87%
Market Closed
Updated:
May 10, 2024
CRISPR Therapeutics AG
Operating Income
|
CRISPR Therapeutics AG
Operating Income Peer Comparison
Comparables:
ADCT
ACIU
BSLN
IDIA
KURN
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Operating Income
-$222.5m
|
CAGR 3-Years
14%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Operating Income
-$166m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
AC Immune SA
NASDAQ:ACIU
|
Operating Income
-CHf53.6m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Operating Income
CHf19.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Idorsia Ltd
SIX:IDIA
|
Operating Income
-CHf803m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-152%
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Operating Income
-CHf8.7m
|
CAGR 3-Years
9%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
See Also
What is CRISPR Therapeutics AG's Operating Income?
Operating Income
-222.5m
USD
-222.5m
USD
Based on the financial report for Dec 31, 2023, CRISPR Therapeutics AG's Operating Income amounts to -222.5m USD.
What is CRISPR Therapeutics AG's Operating Income growth rate?
Operating Income CAGR 5Y
-7%
-7%
Over the last year, the Operating Income growth was 67%. The average annual Operating Income growth rates for CRISPR Therapeutics AG have been 14% over the past three years , -7% over the past five years .
You don't have any saved screeners yet
